Enlivex Ltd. (ENLV)
0.254
-0.02
(-8.30%)
USD |
NASDAQ |
Oct 09, 16:00
0.2454
-0.01
(-3.39%)
After-Hours: 20:00
Enlivex Net Income (Quarterly) : 1.892B for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.892B |
| December 31, 2025 | 1.243B |
| September 30, 2025 | -2.205M |
| June 30, 2025 | -1.868M |
| March 31, 2025 | -3.452M |
| December 31, 2024 | -5.176M |
| September 30, 2024 | -2.602M |
| June 30, 2024 | -3.096M |
| March 31, 2024 | -4.14M |
| December 31, 2023 | -9.095M |
| September 30, 2023 | -5.963M |
| June 30, 2023 | -6.792M |
| March 31, 2023 | -7.218M |
| December 31, 2022 | -7.189M |
| September 30, 2022 | -5.733M |
| June 30, 2022 | -9.913M |
| March 31, 2022 | -8.225M |
| December 31, 2021 | -4.736M |
| September 30, 2021 | -3.424M |
| June 30, 2021 | -3.108M |
| March 31, 2021 | -3.20M |
| December 31, 2020 | -5.864M |
| September 30, 2020 | -2.125M |
| June 30, 2020 | -3.041M |
| March 31, 2020 | -0.794M |
| Date | Value |
|---|---|
| December 31, 2019 | -2.867M |
| September 30, 2019 | -2.391M |
| June 30, 2019 | -1.461M |
| March 31, 2019 | -2.665M |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | -0.569M |
| September 30, 2017 | -1.071M |
| June 30, 2017 | -1.633M |
| March 31, 2017 | -2.672M |
| December 31, 2016 | -3.073M |
| September 30, 2016 | -4.67M |
| June 30, 2016 | -3.685M |
| March 31, 2016 | -4.594M |
| December 31, 2015 | -4.829M |
| September 30, 2015 | -3.551M |
| June 30, 2015 | -3.686M |
| March 31, 2015 | -3.299M |
| December 31, 2014 | -3.152M |
| September 30, 2014 | -2.111M |
| June 30, 2014 | -1.114M |
| March 31, 2014 | |
| December 31, 2013 | -0.777M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Polyrizon Ltd. | -- |
| NovelStem International Corp. | -0.0858M |
| Brainstorm Cell Therapeutics, Inc. | -3.855M |
| Summit Therapeutics, Inc. | -215.70M |
| PeptiDream Inc. | -7.182M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | -1.892B |
| EPS Diluted (Quarterly) | 97.84 |
| Enterprise Value | 16.19M |
| Earnings Yield | 189.8K% |
| Normalized Earnings Yield | 14634.76 |